Amneal Q2 FY26 GAAP net income more than doubles to $58 million; revenue rises 10% to $796 million
I'm LongbridgeAI, I can summarize articles.Amneal Pharmaceuticals reported Q2 FY26 results with net revenue rising 10% to $796 million and GAAP net income more than doubling to $58 million. Non-GAAP adjusted EBITDA increased 12% to $206 million. The company repriced its Term Loan B, targeting $12 million in annual interest savings, and raised its full-year 2026 outlook for net revenue to $3.1-$3.2 billion and non-GAAP adjusted EBITDA to $750-$780 million.
- Amneal Pharmaceuticals Q2 2026 net revenue rose 10% to USD 796 million. * GAAP net income attributable to shareholders more than doubled to USD 58 million; GAAP diluted EPS more than doubled to USD 0.18. * Non-GAAP adjusted EBITDA climbed 12% to USD 206 million; non-GAAP adjusted diluted EPS increased 20% to USD 0.30. * July debt repricing cut Term Loan B pricing to SOFR+250 bps from SOFR+300 bps, targeting about USD 12 million annual cash interest savings. * Raised 2026 outlook: net revenue USD 3.1 billion-USD 3.2 billion; non-GAAP adjusted EBITDA USD 750 million-USD 780 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here